Catalog No.
Product Name
Application
Product Information
Citations
-
KLK5 Inhibitor
Kallikrein 5-IN-2 is a selective inhibitor of Kallikrein 5 (KLK5), exhibiting a pIC50 of 7.1. This compound demonstrates the ability to regulate epidermal shedding, potentially alleviating related inflammation and pruritus. Kallikrein 5-IN-2 serves as a valuable tool in research focused on dermatological conditions and the modulation of skin barrier function. -
Plasma Kallikrein Inhibitor
Sebetralstat is a selective inhibitor of plasma kallikrein, a serine protease involved in the kallikrein-kinin system. This compound demonstrates significant activity in modulating bradykinin levels, making it relevant for investigating metabolic diseases and conditions associated with dysregulated kallikrein activity. Its ability to inhibit plasma kallikrein positions Sebetralstat as a valuable tool for research into therapeutic strategies for associated pathologies. -
Coagulation Factor XII/Kallikrein Inhibitor
D-Pro-Phe-Arg-Chloromethylketone is a selective inhibitor of coagulation factor XII and plasma kallikrein. This compound is essential for studying the mechanisms of thrombosis and inflammation, making it a valuable tool for research in cardiovascular diseases and related fields. Its ability to inhibit these factors can provide insights into the regulation of hemostasis and the inflammatory response. -
Plasma Kallikrein Inhibitor
KVD-001 is a potent inhibitor of plasma kallikrein, a serine protease involved in the kallikrein-kinin system. This compound demonstrates significant biological activity by modulating vascular permeability and inflammatory responses. KVD-001 is applicable in research focused on diabetic macular edema, providing valuable insights into therapeutic interventions for ocular diseases. -
Tissue Kallikrein Inhibitor
FE-999024 is a selective inhibitor of tissue kallikrein, a serine protease involved in various physiological processes. This compound has demonstrated the ability to reduce cancer cell invasion by up to 39% and to decrease eosinophilia in models of allergic inflammation. FE-999024 serves as a valuable tool in research focused on cancer, inflammation, and immunology, contributing to a deeper understanding of these biological pathways. -
Plasma Kallikrein Inhibitor
Berotralstat is an orally active plasma kallikrein inhibitor that demonstrates significant potential in the modulation of vascular permeability. By inhibiting plasma kallikrein, Berotralstat has been shown to reduce brain edema, making it a valuable candidate for research in glioblastoma and hereditary angioedema. Its application in these areas may contribute to improved therapeutic strategies for conditions characterized by excessive vascular leakage and inflammation. -
Substrate for Kallikrein
D-Val-Leu-Arg-pNA acetate serves as a substrate for the serine protease kallikrein. It enables the assessment of kallikrein activity through the release of p-nitroaniline upon peptide cleavage. This compound is valuable for research applications focused on the role of kallikrein in various physiological and pathological processes, providing insights into its functions in inflammation and fluid regulation. -
Plasma Kallikrein Inhibitor
PKSI-527 is a highly selective plasma kallikrein inhibitor that targets the kallikrein-kinin system. It demonstrates significant potential in suppressing collagen-induced arthritis (CIA) by modulating inflammatory responses. PKSI-527 serves as a valuable tool for studying the role of plasma kallikrein in various pathological conditions and may aid in the development of therapeutic strategies for rheumatoid arthritis. -
Kallikrein Inhibitor
Feniralstat is a potent kallikrein inhibitor that exhibits an IC50 of 6.7 nM for human plasma kallikrein (pKal). This pyrazole derivative demonstrates selectivity, showing no inhibition on human KLKl, human FXIa, or human Factor XIIa, with IC50 values greater than 40 μM. Feniralstat is a valuable tool for investigating kallikrein-related pathways and may have implications in research focused on coagulation and inflammatory processes. -
Plasma Kallikrein Inhibitor
Berotralstat dihydrochloride is an orally active inhibitor of plasma kallikrein, a serine protease involved in the Bradykinin pathway. This compound has demonstrated efficacy in reducing brain edema and is under investigation for its therapeutic potential in glioblastoma and hereditary angioedema. Research applications include the study of inflammatory pathways and the modulation of vascular permeability in various disease states. -
Kallikrein Inhibitor
PPACK II diTFA is an irreversible inhibitor targeting glandular and plasma kallikreins. It demonstrates specificity in modulating kallikrein activity, making it a valuable tool for studies focused on coagulation, inflammation, and related pathways. This compound is essential for research exploring the physiological roles of kallikreins and their potential implications in various diseases. -
Plasma Kallikrein Inhibitor
Plasma kallikrein-IN-4 is a selective inhibitor of plasma kallikrein, exhibiting an IC50 of 0.016 μM against human plasma kallikrein. This compound effectively modulates the kallikrein-kinin system, contributing to its potential as a therapeutic agent in conditions associated with dysregulated bradykinin signaling. Plasma kallikrein-IN-4 is valuable for research applications focusing on cardiovascular diseases, inflammation, and pain signaling pathways. -
Kallikrein Inhibitor
LSP-249 is a potent plasma kallikrein inhibitor with an EC50 of less than 100 nM in cellular assays. This compound is currently being investigated for its therapeutic potential in treating angioedema. Its ability to modulate kallikrein activity makes it a valuable tool for research focused on vascular permeability and related disorders. -
Prekallikrein Inhibitor
Donidalorsen sodium is an antisense oligonucleotide that selectively targets prekallikrein (PKK). By binding to and promoting the degradation of PKK mRNA in the liver, Donidalorsen sodium effectively inhibits kallikrein activity and diminishes Bradykinin production. This reagent is particularly valuable for research applications related to hereditary angioedema. -
Kallikrein 5 Inhibitor
Eflumenibep alfa is a Kallikrein 5 inhibitor that exhibits anti-inflammatory properties. This fusion protein consists of human SPINK2 linked to the human IgG1 Fc fragment at the C-terminus, enabling it to effectively modulate inflammatory pathways. It is primarily used in research applications focused on inflammatory diseases and conditions related to kallikrein signaling. -
KLK6 Inhibitor
DKFZ-633 is a potent inhibitor of KLK6, exhibiting an IC50 of 250 nM against human KLK6. This compound covalently labels active KLK6 with high specificity, enabling the efficient pull-down and capture of endogenous KLK6 from cell-conditioned media. DKFZ-633 is an essential reagent for studying the role of KLK6 and its regulatory mechanisms, particularly in the context of head and neck cancer research. -
Plasma Kallikrein (pKal) Inhibitor
pKal-IN-1 is a selective inhibitor of plasma kallikrein (pKal), an enzyme involved in the kallikrein-kinin system, which plays a significant role in inflammatory processes. This compound has demonstrated the ability to modulate vascular permeability and inflammation, making it a valuable tool for studying diabetic macular edema and diabetic retinopathy. pKal-IN-1 can be utilized in various research applications aimed at understanding the therapeutic potential in treating these diabetes-related ocular conditions. -
Kallikrein Inhibitor
Ecallantide is a specific inhibitor of plasma kallikrein, effectively reducing the production of bradykinin. Its primary biological activity lies in the prevention of acute angioedema attacks, making it a valuable tool for research into conditions related to excessive bradykinin activity. Ecallantide is applicable in studies focusing on inflammatory responses and therapeutic interventions for angioedema disorders. -
Kallikrein Inhibitor
PPACK II is a potent irreversible inhibitor of glandular and plasma kallikreins, targeting their enzymatic activity. This compound is essential for studying the physiological roles of kallikreins in various biological processes, including inflammation and pain modulation. It is valuable for research applications focused on understanding kallikrein-related pathways and developing therapeutic strategies for associated diseases. -
Kallikrein-5 Inhibitor
GSK951 is a potent and selective inhibitor of Kallikrein-5 (KLK5), demonstrating an IC50 of 250 pM with over 100-fold selectivity against KLK7 and KLK14. This compound is designed for effective epidermal delivery and has been shown to reduce transepidermal water loss while decreasing pro-inflammatory cytokine expression. GSK951 is valuable for research applications in inflammation and immunology, particularly in studies related to Netherton syndrome. -
Kallikrein Inhibitor
Feniralstat hydrochloride is a potent inhibitor of kallikrein, with an IC50 value of 6.7 nM for human plasma kallikrein (pKal). This pyrazole derivative exhibits selectivity, showing no significant inhibition on human Kallikrein KLKl, FXIa, or Factor XIIa (IC50 values greater than 40 μM). Feniralstat is useful in research applications studying kallikrein's role in various biological processes and disease states, particularly in conditions associated with dysregulated kallikrein activity. -
Prekallikrein synthesis reducer
Onvuzosiran is a small interfering RNA (siRNA) that effectively reduces the synthesis of prekallikrein, a key component in the contact activation pathway of blood coagulation. By targeting and silencing the gene responsible for prekallikrein production, Onvuzosiran plays a crucial role in research focused on thrombosis, inflammatory responses, and related cardiovascular disorders. This reagent is essential for studies investigating the modulation of the coagulation cascade and the development of novel therapeutic strategies. -
FXIa/Kallikrein Inhibitor
FXIa/Plasma kallikrein-IN-1 is a potent inhibitor of coagulation factor XIa (FXIa) and plasma kallikrein, exhibiting Ki values of 187.70 nM and 151.6 nM, respectively. This compound serves as a valuable tool for investigating thromboembolic diseases and related disorders. Its selective inhibition of these targets can facilitate the exploration of pathological mechanisms and the development of therapeutic strategies for coagulopathies. -
Plasma Kallikrein Inhibitor
Plasma kallikrein-IN-3 is a potent inhibitor of plasma kallikrein, exhibiting an IC50 of 0.15 μM. This compound is relevant for research into hereditary angioedema, diabetic macular edema, and diabetic retinopathy. Its selective inhibition of plasma kallikrein supports investigations into related pathophysiological processes and therapeutic interventions. -
Protease Inhibitor
ONO-3307 is a potent protease inhibitor that acts competitively against a range of proteases, including trypsin, thrombin, plasma kallikrein, plasmin, pancreatic kallikrein, and chymotrypsin. This compound has demonstrated efficacy in alleviating endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rat models. ONO-3307 is valuable for research into thrombosis and various protease-mediated diseases, providing insights into potential therapeutic strategies. -
PKK Inhibitor
Donidalorsen is an antisense oligonucleotide that selectively targets prekallikrein (PKK). By binding to and degrading PKK mRNA in the liver, Donidalorsen effectively inhibits kallikrein activity and reduces bradykinin production. This reagent is valuable for research focused on hereditary angioedema and related pathophysiological studies. -
KLK6 Inhibitor
DKFZ-251 is an inhibitor of the kininogenase-related peptidase KLK6, demonstrating an IC50 of 0.47 μM. It also shows inhibitory activity against KLK5 and KLK7 with IC50 values of 1.1 nM and 73 nM, respectively. This compound functions by transiently acylating the catalytic serine of KLK6, resulting in a stable acyl-enzyme complex that effectively inhibits enzymatic activity. DKFZ-251 serves as a phenotypic modulator, impacting cell proliferation and regulating epithelial-mesenchymal transition (EMT), making it a valuable tool in studies related to head and neck cancer. -
Kallikrein Inhibitor
KKI-5 is a selective inhibitor of tissue kallikrein, demonstrating significant activity in reducing breast cancer cell invasion. This compound is valuable for research into cancer biology and the mechanisms of metastasis, offering insights into potential therapeutic strategies targeting kallikrein-related pathways.
